Andrey Kozlov

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.

Part of HSBC Holdings Plc, HSBC Investment Bank Plc provides stock broking services. The company is based in London, UK.

Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom.

Vascular Flow Technologies Ltd. develops vascular devices. It offers Spiral Flow Peripheral Vascular Graft, Spiral Flow AV Access Graft, Spiral Laminar Flow, Power of Spiral Laminar Flow and unique design eliminates graft turbulences. The company was founded by Peter Stonebridge, Brian Howlett, Graeme Houston and John B.C. Dick and headquartered in Dundee, the United Kingdom.

Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom.

Image Analysis Ltd. operates as an imaging clinical research organization. It supports optimal design and data management of clinical trials. The company was founded by Olga Kubassova in 2007 and is headquartered in London, the United Kingdom.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021.